Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3PDL8)

Drug Name

ARO-ANG3 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Dyslipidemia	5C80-5C81	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ANGPTL3 messenger RNA (ANGPTL3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vupanorsen	DMN6J18	Hypertriglyceridemia	5C80.1	Phase 2	[3]
ISIS-ANGPTL3	DM9Y51T	Hyperlipidaemia	5C80	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ANGPTL3 messenger RNA (ANGPTL3 mRNA)	TT59GO7	ANGL3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04832971) A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia. U.S.National Institutes of Health.
2	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.
3	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
4	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.